All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Filters

92 (0,124s)

Result

Pleiotropic effects of niacin: current possibilities for its clinical use

Niacin was the first hypolipidemic drug to significantly reduce both major cardiovascular events and mortality in patients with cardiovascular disease. Niacin favorably potent hypolipidemic drugs for increasing HDL-C. Moreover, ...

CD - Makromolekulární chemie

  • 2016
  • Jx
  • Link
Result

2010: year of niacin?

Niacin represents the traditional lipid lowering drug. It increases before all HDL-C, but influences positively also LDL-C and triglycerides levels....

FA - Kardiovaskulární nemoci včetně kardiochirurgie

  • 2010
  • Jx
Result

Nicotinic acid plus laropiprant

Nicotinic acid (niacin) is the first ever hypolipidemic agent to have been introduced in clinical practice. Niacin is currently recommended particularly as part of combination therapy with statins....

FA - Kardiovaskulární nemoci včetně kardiochirurgie

  • 2011
  • Jx
Result

Fixed combination niacin/laropiprant - revival of the use of a class of lipid-modifying drugs

Niacin (nicotinic acid) reduces aterogennic particles and increases protective HDL-cholesterol. The combination with laropiprant reduces side effects, especially flushing....

FA - Kardiovaskulární nemoci včetně kardiochirurgie

  • 2010
  • Jx
Result

Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?

Niacin is considered to be a powerful drug for the treatment of lipid (decreased parameters of cardiovascular risk) is achieved by adding niacin to existing, several adverse effects of the treatment were observed; therefore, nia...

FA - Kardiovaskulární nemoci včetně kardiochirurgie

  • 2015
  • Jx
  • Link
Result

Combination of niacin and laropiprant: another possibility of influencing not only dyslipidemia

The derivate of nicotin acid ? niacin provides significant potential to affect dyslipidemia with stopping progression of atherosclerosis at the same time. The modern formulation offers a wider use and lower incidence of side effects....

FA - Kardiovaskulární nemoci včetně kardiochirurgie

  • 2011
  • Jx
Result

Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia

Lipid lowering and safety of the treatment with niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia and mixed dyslipidaemia......

FA - Kardiovaskulární nemoci včetně kardiochirurgie

  • 2010
  • Jx
Result

The increase of breath ammonia induced by niacin ingestion quantified by selected ion flow tube mass spectrometry

The ingestion of relatively large doses of the vitamin niacin by healthy) the ingestion of 200 mg of immediate-release niacin, (ii) as (i) but preceded mg of slow-release niacin. On-line breath analysis was carried out usin...

CF - Fyzikální chemie a teoretická chemie

  • 2006
  • Jx
Result

Determination of vitamin B6 and niacin by HPLC method

For vitamin B6 and niacin determination in food supplements and foods mainly of animal origin the ion pairing RP. HPLC following the acidic and enzymatic hydrolysis is difference in sensitivity of testing strain to individual vitamers. In ca...

GM - Potravinářství

  • 2001
  • D
Result

Extended-release niacin/laropiprant fixed combination

(a). Nicotinic acid (niacin) modifies all these lipoprotein classes by about 20% (the rule niacin was used to treat dyslipidemia as early as in 1950, it is prescribed rather dosage and from adherence to niacin therapy....

FB - Endokrinologie, diabetologie, metabolismus, výživa

  • 2010
  • Jx
  • 1 - 10 out of 92